Immunotherapy: latest news - GoINPHARMA
Tuesday, 26 March 2019 - 13:42

Immunotherapy

Rude awakening for immunotherapy sector

Last Friday’s news about the failed Phase III clinical trial with immunotherapy Keytruda in combination with Incyte’s cancer therapy epacadostat not only has wiped $4m from the US biotech’s capitalization over few hours, but has also risen much concern among…

The immunotherapy market

The Financial Times has published  today a very short review about the immunotherapy market. This business is currently dominated by Merck & Co and Bristol-Myers Squibb with blockbusters Keytruda and Opdivo, however these are already facing competition from Roche, Pfizer…

Oncology business to keep leading pharma market in 2018

Oncology will maintain its leading position in the pharma industry in 2018. The cancer drug market will be worth approximately $100bn in 2017. The 30 main cancer drugs have generated approximately 12% of their respective manufacturers’ revenues over the first…

US NIH partners with 11 pharma groups to develop new immunotherapies

US NIH (National Institutes of Health) has entered into a cooperation agreement with 11 pharmaceutical companies in order to develop new biomarkers to advance new immunotherapies targeting cancer. The eleven companies that have signed the agreement include AbbVie, Roche, Bristol-Myers…

Research on new cancer therapies: state of the art

The Economist has chosen the state of the art of cancer therapies as the latest Technology Quarterly’s topic. Cancer kills 8.8m people each year and affects at least one on three people in western countries. Although this death rate is…

Immunotherapy takes risky gamble

Many analysts believe there is excessive enthusiasm in the pharmaceutical market about immunotherapies for cancer. Merck & Co. and Bristol-Myers Squibb lead the industry until now, with their respective immunotherapies Keytruda and Opdivo, both “checkpoint inhibitors”, generating together over $4bn…